| Renal cell carcinoma(RCC) is one of the highest degree of malignant tumor among the urogenital system, which has characteristics of rapid progression and highly mortality. Due to RCC is not sensitive to radiotherapy and chemotherapy,nonspecific immune therapy, including interleukin-2 and interferon -? has become the main treatment of advanced RCC in recent 20 years. However, only about 10% of advanced RCC are in remission. Extensive researches about biology and molecular mechanism have found that VHL, Ras gene mutation and hypermethylation are associated with the occurrence and development of RCC. Therefore, these mutant genes and signaling pathways as targets were closed and blocked which acting as targeted drugs have been developed to improve the prognosis of advanced RCC and offer more options for the treatment of advanced RCC. This article reviewed the various of targeted drugs for treatment advanced RCC, and analyzed individual therapy of targeting drugs in terms of histological type, clinical characteristics, biomarkers, drug toxicity, etc. |
PDF Full Text Request